Fewer than one in 10 people eligible to benefit from GLP-1 drugs such as Wegovy have access to them, states the WHO as it publishes its initial recommendations on the medications.
Given in excess of 1,000,000,000 people worldwide currently living with obesity, it is calling for broader and more equitable access to this class of drugs.
Per estimates, more than two billion could be living with obesity by 2030 unless action is taken.
"The new guidelines acknowledges that excess weight is a chronic disease that can be treated with comprehensive and lifelong treatment," stated the agency's head Tedros Adhanom Ghebreyesus.
High costs, constrained manufacturing, and supply-chain constraints are key hurdles to broad availability to the jabs that can assist patients in reducing significant body mass, explains the body.
Skinny Jab Shortage
Even under the present best projected scenario, the manufacturing of GLP-1 therapies might only reach around 100 million people – under 10% of the global need, according to the health organization.
The recommendation encourages nations and manufacturers to widen access, through measures including voluntary licensing.
A patent on semaglutide – the main ingredient of the drug Wegovy – is scheduled to end in multiple countries in 2026.
The Way Weight-Loss Drugs Operate
GLP-1 drugs replicate a biological compound to reduce digestion speed, curb appetite and enhance feelings of fullness so individuals reduce food intake.
People typically see weight reduction within a few weeks of commencing the once-weekly jabs.
Studies suggests people may see weight return a year later of discontinuing the treatment, when their typical food cravings resume.
To be overweight or obese increases your likelihood for experiencing medical conditions, like type 2 diabetes, cardiovascular issues, stroke, and some cancers.
Excess weight concerns people in all nations and was linked to over three and a half million deaths worldwide in 2024, as per the health agency.
